 |
| A number of physicians swear by the effectiveness of Ivermectin, an antiparasitic drug commercially available only for veterinary use, as a treatment or preventivemedicine against COVID-19. (Photo by=AFP) |
[Asia News Communication = Reporter Reakkana] MANILA— IP Biotech Inc. (IPB), in partnership with Ambica International Inc., announced on Saturday they are interested in applying for clinical trials for ivermectin with the Food and Drug Administration (FDA). “IPB and Ambica seek to work closely with regulators and an independently run clinical trial to validate ivermectin as a treatment for COVID19.” IPB Chairman Enrique Gonzales said in a statement on Saturday, April 10, PH Inquirer said.
IPB said a number of physicians in the country are recommending the use of ivermectin in the treatment against COVID-19, saying the antiparasitic drug has been used to treat COVID-19 patients in Honduras and other regions of the world. “While vaccines are the core strategy to resolve this pandemic, we must also supplement this approach with affordable treatments,” Enrique added.
Deepu Bhatia, Vice President of Ambica, said he sees a potential for ivermectin use against COVID-19. “We see tremendous potential in the use of ivermectin in the treatment of COVID-19, subject to clinical trial validation and regulatory approval,” she said. Meanwhile, House Deputy Speaker Bernadette Herrera urged regulators to “keep an open mind” on ivermectin.
